Skip to main content
. 2021 Dec 1;12(6):2934–2949. doi: 10.1016/j.apsb.2021.11.020

Figure 6.

Figure 6

Systemic anti-tumor immune responses and tumor growth inhibition potency triggered by JQ-1@PSNs-R-based photothermal-mediated immunotherapy. (A) Schematic illustration of photothermal-mediated immunotherapy and the detections. (B) Percentages of CD4+ IFN-γ+ T cells (Th1 cells) and CD8+ IFN-γ+ T cells (CTLs) in spleens. (C) Antigen-specific IgG, IgG1 and IgG2a in serum. (D) IFN-γ secreted by splenocytes. (E) Tumor growth after photothermal-mediated immunotherapy (8 mice per group). (F) Survival of mice after photothermal-mediated immunotherapy (8 mice per group). (G) Images of scab healing of the same mouse after photothermal-mediated immunotherapy; (H) Images of hematoxylin-eosin stained tumor sections to confirm the prevention of tumor recurrence and metastasis after photothermal-mediated immunotherapy (HE stain, × 400). Data were mean ± SEM, n = 3–4 and analyzed by one-way ANOVA. ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001 and ∗∗∗∗P < 0.0001. ns, not significant.